• Total net turnover increased 0.9% (3.2% in local currencies) to €820.0°million (Q3/08: €812.4°million)⁽¹⁾
• Adjusted EBITDA decreased 3.1% (1.5% in local currencies) to €285.3°million (Q3/08: €294.4°million)⁽¹⁾
• Pantoprazole sales resilient after loss of exclusivity. Newly-launched OTC variant performing strongly in Europe
• Roflumilast (Daxas^®) submitted to FDA and agreement with Forest L

Asthma is not controlled in almost two thirds of affected children according to the largest ever international survey undertaken in paediatric asthma(1).

This poor result is despite apparently straightforward clinical guidelines and widely available preventative treatments for children with asthma.